-+ 0.00%
-+ 0.00%
-+ 0.00%

Curis Announces $80.8M PIPE Financing Backed By Healthcare-Focused Institutional Investors; Includes ~$20.2M Initial Proceeds,

Benzinga·01/07/2026 13:47:48
Listen to the news

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it has entered into a securities purchase agreement with new and existing healthcare-focused, high-quality institutional investors and certain insiders of the Company for a private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds to the Company of approximately $20.2 million, in each case before placement agent fees and offering expenses. The PIPE financing is expected to close on or about January 8, 2026, subject to the satisfaction of customary closing conditions.

Laidlaw & Company (UK) Ltd. is acting as sole placement agent for the PIPE financing.